

Amendments to the Specification

Please cancel all the drawings from this application.

Please amend the paragraph starting in the specification on page 53, line 4 as follows:

Compounds, which preferentially inhibit Akt/Pdk activity are shown in the table designated Group 1 compounds figure 1.

Please amend the paragraph starting in the specification on page 61, line 17 as follows:

Compounds, which preferentially inhibit Chk activity are shown in the table designated Group 2 compounds figure 2.

Please amend the paragraph starting in the specification on page 63, line 20 as follows:

Compounds, which preferentially inhibit Akt and/or Pdk and the VEGF-R activity are shown in the table designated Group 3 compounds figure 3.

Please amend the paragraph starting in the specification on page 64, line 3 as follows:

Further, the invention is explained in more detail by the enclosed drawings and examples.

Figures:

Figure Group 1 compounds: preferred compounds inhibiting preferentially Akt, Pdk kinases











Figure Group 2 compounds: preferred compounds inhibiting preferentially Chk kinases






Figure Group 3 compounds: preferred compounds inhibiting preferentially Akt and/or Pdk and VEGF-R kinases

Please insert the following onto page 64, line 11 of the application.


Group 1 compounds:

444	
446	
452	
468	



471		
474		
486		
493		
498		

515	  
535	
546	


394



395




255





242	<p>2-bromo-6-(2-(2-(2,2,2-trifluoroethyl)acetamido)ethyl)uracil</p>
220	<p>2-bromo-6-(2-(2-(1-methyl-1H-imidazol-2-yl)ethyl)acetamido)uracil</p>
389	<p>2-bromo-6-(2-(2-(2-methyl-1H-imidazol-2-yl)ethyl)acetamido)uracil</p>
548	<p>2-bromo-6-(2-(2-(2-(2,2,2-trifluoroethyl)acetamido)ethyl)acetamido)uracil</p>



533







524







521






508





504



492



540




Group 2 compounds:

490	
402	
399	
476	
450	
431	
251	
99	

A16	
A17	
A18	
103	
104	
105	
A19	

123	
124	
125	
126	
127	
129	
130	
131	

132	
133	
699	
700	
701	
702	
703	
704	



Group 3 compounds:

	structures
200	
207	
222	
230	
233	

239	
241	
242	
246	
254	
259	
261	
274	

502	
508	
509	
411	
414	
535	
539	
540	
520	

546	
547	